TY - JOUR
T1 - Retinal pathology occurs in stiff-person syndrome
AU - Lambe, Jeffrey
AU - Rothman, Alissa
AU - Prince, Jerry
AU - Saidha, Shiv
AU - Calabresi, Peter A.
AU - Newsome, Scott D.
N1 - Funding Information:
This study was funded by NIH/NINDS (R01NS082347 to P.A.C.).
Funding Information:
J. Lambe and A. Rothman report no disclosures relevant to the manuscript. J. Prince is a founder of Sonovex, Inc. and serves on its Board of Directors; has received consulting fees from JuneBrain LLC; and is PI on research grants to Johns Hopkins from 12Sigma Technologies and Biogen. S. Saidha has received consulting fees from Medical Logix for the development of CME programs in neurology and has served on scientific advisory boards for Biogen, Genzyme, Genentech Corporation, EMD Serono, and Celgene; is the PI of investigator-initiated studies funded by Genentech Corporation and Biogen Idec; received support from the Race to Erase MS Foundation; has received equity compensation for consulting from JuneBrain LLC, a retinal imaging device developer; and is the site investigator of a trial sponsored by MedDay Pharmaceuticals. P. Calabresi has received consulting fees from Disarm and Biogen and is PI on grants to JHU from Biogen and Annexon. S. Newsome has received consultant fees for scientific advisory boards from Biogen, Genentech, Celgene, and EMD Serono; is an advisor for Gerson Lehrman Group; is a clinical adjudication committee member for a MedDay Pharmaceuticals clinical trial; and has received research funding (paid directly to his institution) from Biogen, Novartis, Genentech, National MS Society, Department of Defense, and Patient Centered Outcomes Institute. Go to Neurology.org/N for full disclosures.
Publisher Copyright:
© American Academy of Neurology.
PY - 2020/5/19
Y1 - 2020/5/19
N2 - ObjectiveTo evaluate whether structural and functional changes occur in the afferent visual system of patients with stiff-person syndrome (SPS) and whether these changes correlate with disease burden, given the high concentration of γ-aminobutyric acid receptors, which are generally thought to be involved in SPS pathogenesis, in the retina.MethodsIn this single-center, cross-sectional study, patients with SPS and healthy controls (HCs) underwent optical coherence tomography (OCT), with a subset undergoing high- and low-contrast visual acuity (VA) assessments. Burden of disease was assessed via the number of body regions affected. Individuals with uncontrolled hypertension or comorbid neurologic or ophthalmologic disorders were excluded. Statistical analyses were performed using mixed-effects linear regression models.ResultsThirty-five patients with SPS and 40 age- and sex-matched HCs underwent OCT. A subset of 23 patients with SPS and 28 HCs underwent VA assessments. Relative to HCs, patients with SPS had lower ganglion cell + inner plexiform layer (GCIPL) thicknesses (SPS: 74.36 µm [SD 5.7]; HCs: 76.33 µm [SD 4.2]; p = 0.005), inner nuclear layer thicknesses (SPS: 44.37 µm [SD 2.7]; HCs: 45.18 µm [SD 2.2]; p = 0.042), and 100% (SPS: 53 [SD 9.6]; HCs: 57.5 [SD 6.1]; p = 0.005), 2.5% (SPS: 24.35 [SD 10.1]; HCs: 30.16 [SD 7.7]; p = 0.006), and 1.25% contrast (SPS: 16.41 [SD 10.6]; HCs: 20.84 [SD 8.6]; p = 0.034) letter acuity scores. GCIPL thicknesses correlated with the number of body regions affected in SPS (decrease of 1.25 µm [95% confidence interval, -2.2 to -0.3 µm; p = 0.008] per additional body region affected).ConclusionsRetinal neuronal pathology can occur in SPS. OCT may have utility as a biomarker of disease burden in SPS.
AB - ObjectiveTo evaluate whether structural and functional changes occur in the afferent visual system of patients with stiff-person syndrome (SPS) and whether these changes correlate with disease burden, given the high concentration of γ-aminobutyric acid receptors, which are generally thought to be involved in SPS pathogenesis, in the retina.MethodsIn this single-center, cross-sectional study, patients with SPS and healthy controls (HCs) underwent optical coherence tomography (OCT), with a subset undergoing high- and low-contrast visual acuity (VA) assessments. Burden of disease was assessed via the number of body regions affected. Individuals with uncontrolled hypertension or comorbid neurologic or ophthalmologic disorders were excluded. Statistical analyses were performed using mixed-effects linear regression models.ResultsThirty-five patients with SPS and 40 age- and sex-matched HCs underwent OCT. A subset of 23 patients with SPS and 28 HCs underwent VA assessments. Relative to HCs, patients with SPS had lower ganglion cell + inner plexiform layer (GCIPL) thicknesses (SPS: 74.36 µm [SD 5.7]; HCs: 76.33 µm [SD 4.2]; p = 0.005), inner nuclear layer thicknesses (SPS: 44.37 µm [SD 2.7]; HCs: 45.18 µm [SD 2.2]; p = 0.042), and 100% (SPS: 53 [SD 9.6]; HCs: 57.5 [SD 6.1]; p = 0.005), 2.5% (SPS: 24.35 [SD 10.1]; HCs: 30.16 [SD 7.7]; p = 0.006), and 1.25% contrast (SPS: 16.41 [SD 10.6]; HCs: 20.84 [SD 8.6]; p = 0.034) letter acuity scores. GCIPL thicknesses correlated with the number of body regions affected in SPS (decrease of 1.25 µm [95% confidence interval, -2.2 to -0.3 µm; p = 0.008] per additional body region affected).ConclusionsRetinal neuronal pathology can occur in SPS. OCT may have utility as a biomarker of disease burden in SPS.
UR - http://www.scopus.com/inward/record.url?scp=85084930382&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084930382&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000008943
DO - 10.1212/WNL.0000000000008943
M3 - Article
C2 - 31924684
AN - SCOPUS:85084930382
SN - 0028-3878
VL - 94
SP - E2126-E2131
JO - Neurology
JF - Neurology
IS - 20
ER -